AMRX logo

Amneal Pharmaceuticals (AMRX) EBIT

annual EBIT:

$203.58M+$33.22M(+19.50%)
December 31, 2024

Summary

  • As of today (May 29, 2025), AMRX annual earnings before interest & taxes is $203.58 million, with the most recent change of +$33.22 million (+19.50%) on December 31, 2024.
  • During the last 3 years, AMRX annual EBIT has risen by +$35.89 million (+21.40%).
  • AMRX annual EBIT is now -24.63% below its all-time high of $270.10 million, reached on December 31, 2016.

Performance

AMRX EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherAMRXincome statement metrics

quarterly EBIT:

$94.42M+$48.08M(+103.75%)
March 31, 2025

Summary

  • As of today (May 29, 2025), AMRX quarterly earnings before interest & taxes is $94.42 million, with the most recent change of +$48.08 million (+103.75%) on March 31, 2025.
  • Over the past year, AMRX quarterly EBIT has increased by +$104.24 million (+1061.66%).
  • AMRX quarterly EBIT is now at all-time high.

Performance

AMRX quarterly EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherAMRXincome statement metrics

TTM EBIT:

$307.83M+$104.24M(+51.20%)
March 31, 2025

Summary

  • As of today (May 29, 2025), AMRX TTM earnings before interest & taxes is $307.83 million, with the most recent change of +$104.24 million (+51.20%) on March 31, 2025.
  • Over the past year, AMRX TTM EBIT has increased by +$187.18 million (+155.14%).
  • AMRX TTM EBIT is now at all-time high.

Performance

AMRX TTM EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherAMRXincome statement metrics

EBIT Formula

EBIT = Revenue − COGS − Operating Expenses

AMRX EBIT Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+19.5%+1061.7%+155.1%
3 y3 years+21.4%+303.3%+116.3%
5 y5 years+491.2%+77.3%+237.9%

AMRX EBIT Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+326.8%at high+147.9%at high+348.9%
5 y5-yearat high+326.8%at high+147.9%at high+348.9%
alltimeall time-24.6%+326.8%at high+141.8%at high+238.6%

AMRX EBIT History

DateAnnualQuarterlyTTM
Mar 2025
-
$94.42M(+103.8%)
$307.83M(+51.2%)
Dec 2024
$203.58M(+19.5%)
$46.34M(-42.7%)
$203.58M(+52.7%)
Sep 2024
-
$80.93M(-6.0%)
$133.33M(+5.6%)
Jun 2024
-
$86.12M(-977.1%)
$126.26M(+4.6%)
Mar 2024
-
-$9.82M(-58.9%)
$120.65M(-29.2%)
Dec 2023
$170.36M(-289.8%)
-$23.91M(-132.4%)
$170.36M(-27.1%)
Sep 2023
-
$73.87M(-8.3%)
$233.65M(+14.3%)
Jun 2023
-
$80.52M(+101.9%)
$204.35M(-378.9%)
Mar 2023
-
$39.89M(+1.3%)
-$73.28M(-18.4%)
Dec 2022
-$89.75M(-153.5%)
$39.37M(-11.7%)
-$89.75M(-19.5%)
Sep 2022
-
$44.57M(-122.6%)
-$111.48M(-9.9%)
Jun 2022
-
-$197.11M(-941.8%)
-$123.70M(-186.9%)
Mar 2022
-
$23.41M(+32.7%)
$142.32M(-15.1%)
Dec 2021
$167.69M
$17.64M(-45.5%)
$167.69M(-6.4%)
Sep 2021
-
$32.36M(-53.0%)
$179.11M(+12.1%)
Jun 2021
-
$68.91M(+41.2%)
$159.76M(+51.1%)
DateAnnualQuarterlyTTM
Mar 2021
-
$48.79M(+67.9%)
$105.76M(-4.0%)
Dec 2020
$110.22M(-311.8%)
$29.06M(+123.4%)
$110.22M(+75.3%)
Sep 2020
-
$13.01M(-12.8%)
$62.88M(-46.9%)
Jun 2020
-
$14.91M(-72.0%)
$118.36M(+29.9%)
Mar 2020
-
$53.24M(-391.2%)
$91.11M(-275.1%)
Dec 2019
-$52.04M(-12.0%)
-$18.28M(-126.7%)
-$52.04M(+816.0%)
Sep 2019
-
$68.48M(-654.9%)
-$5.68M(-33.7%)
Jun 2019
-
-$12.34M(-86.3%)
-$8.57M(-96.1%)
Mar 2019
-
-$89.90M(-420.2%)
-$222.12M(+275.5%)
Dec 2018
-$59.15M(-124.4%)
$28.07M(-57.2%)
-$59.15M(+1038.8%)
Sep 2018
-
$65.59M(-129.0%)
-$5.19M(-79.4%)
Jun 2018
-
-$225.88M(-409.1%)
-$25.18M(-109.8%)
Mar 2018
-
$73.07M(-10.9%)
$258.03M(+39.5%)
Dec 2017
$242.38M(-10.3%)
$82.03M(+79.9%)
$184.96M(+79.7%)
Sep 2017
-
$45.60M(-20.5%)
$102.93M(+79.5%)
Jun 2017
-
$57.33M
$57.33M
Dec 2016
$270.10M
-
-

FAQ

  • What is Amneal Pharmaceuticals annual earnings before interest & taxes?
  • What is the all time high annual EBIT for Amneal Pharmaceuticals?
  • What is Amneal Pharmaceuticals annual EBIT year-on-year change?
  • What is Amneal Pharmaceuticals quarterly earnings before interest & taxes?
  • What is the all time high quarterly EBIT for Amneal Pharmaceuticals?
  • What is Amneal Pharmaceuticals quarterly EBIT year-on-year change?
  • What is Amneal Pharmaceuticals TTM earnings before interest & taxes?
  • What is the all time high TTM EBIT for Amneal Pharmaceuticals?
  • What is Amneal Pharmaceuticals TTM EBIT year-on-year change?

What is Amneal Pharmaceuticals annual earnings before interest & taxes?

The current annual EBIT of AMRX is $203.58M

What is the all time high annual EBIT for Amneal Pharmaceuticals?

Amneal Pharmaceuticals all-time high annual earnings before interest & taxes is $270.10M

What is Amneal Pharmaceuticals annual EBIT year-on-year change?

Over the past year, AMRX annual earnings before interest & taxes has changed by +$33.22M (+19.50%)

What is Amneal Pharmaceuticals quarterly earnings before interest & taxes?

The current quarterly EBIT of AMRX is $94.42M

What is the all time high quarterly EBIT for Amneal Pharmaceuticals?

Amneal Pharmaceuticals all-time high quarterly earnings before interest & taxes is $94.42M

What is Amneal Pharmaceuticals quarterly EBIT year-on-year change?

Over the past year, AMRX quarterly earnings before interest & taxes has changed by +$104.24M (+1061.66%)

What is Amneal Pharmaceuticals TTM earnings before interest & taxes?

The current TTM EBIT of AMRX is $307.83M

What is the all time high TTM EBIT for Amneal Pharmaceuticals?

Amneal Pharmaceuticals all-time high TTM earnings before interest & taxes is $307.83M

What is Amneal Pharmaceuticals TTM EBIT year-on-year change?

Over the past year, AMRX TTM earnings before interest & taxes has changed by +$187.18M (+155.14%)
On this page